Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Theodore Phillips

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
The Lancet. Neurology|February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyEva Havrdova, Steven Galetta, Michael Hutchinson, et al.
Annals of Neurology|April 25, 2006
Immune surveillance in multiple sclerosis patients treated with natalizumabOlaf Stüve, Christina M Marra, Keith R Jerome, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM studyMariko Kita, Robert J Fox, J Theodore Phillips, et al.
Neurology and Therapy|December 15, 2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing ExperienceRalf Gold, J Theodore Phillips, Eva Havrdova, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Archives of Neurology|October 13, 2006
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisOlaf Stüve, Christina M Marra, Amit Bar-Or, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Neurology|March 29, 2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L Arnold, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
The Lancet. Neurology|February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyEva Havrdova, Steven Galetta, Michael Hutchinson, et al.
Annals of Neurology|April 25, 2006
Immune surveillance in multiple sclerosis patients treated with natalizumabOlaf Stüve, Christina M Marra, Keith R Jerome, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM studyMariko Kita, Robert J Fox, J Theodore Phillips, et al.
Neurology and Therapy|December 15, 2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing ExperienceRalf Gold, J Theodore Phillips, Eva Havrdova, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Archives of Neurology|October 13, 2006
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisOlaf Stüve, Christina M Marra, Amit Bar-Or, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Neurology|March 29, 2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L Arnold, et al.
Pageof 5